Windlas Biotech · risk themes across the available quarters.
Bear-case history
Management repeatedly deflected questions on injectable utilization levels and sequential revenue progression, citing competitive sensitivity. Last disclosed injectable revenue was 'not encouraging' in Q4 FY25. Quarter-on-quarter improvement was claimed but not quantified.
Trade generics showed 25% YoY growth but 'lower' sequential growth vs Q4 FY25. Analyst questioned annual run rate target (₹200-225 crore); management attributed variation to tender timing and seasonal effects, advising annual rather than quarterly view.
Analyst asked about wallet share improvement in CDMO business with Schedule M implementation driving migration from unorganized players. Management acknowledged inability to track wallet share due to lack of published data and customer confidentiality, only monitoring client concentration metrics.
Analyst correctly noted that current depreciation run rate excludes Plant 6 impact. When Plant 6 is capitalized (expected late FY26), additional depreciation will begin, creating headwind to margins. Management confirmed 'extra depreciation starts kicking in' upon capitalization.
Q3 Trade Generics growth slowed to 7% YoY versus 18% for 9M FY26 and historical quarters of up to 74%. Management attributed this to competitive intensity from new entrants, institutional order lumpiness, and execution factors. Peers with 2.5x the base are growing faster.
Management admitted injectable capacity utilization has been lower than expectations but declined to disclose specific numbers citing competitive sensitivity. No clear timeline provided to reach 70-80% utilization target.
An analyst directly asked for 9-month net cash generation which management deflected, stating balance sheet is only limited reviewed and they want to refrain from sharing. This limits visibility into working capital efficiency and leverage.
Over 95% of sales are domestic India. Any policy changes (NLEM pricing, PLI scheme changes), regulatory shifts, or industry volume growth data gaps (government program purchases not captured by IQVIA/Awaz) could impact revenue visibility.